葫芦素B通过靶向ZNF70抑制NLRP3/STAT3信号轴减轻dss诱导的实验性结肠炎。

IF 5.3 2区 医学 Q2 IMMUNOLOGY
Inflammopharmacology Pub Date : 2025-09-01 Epub Date: 2025-08-12 DOI:10.1007/s10787-025-01898-5
Shen Cao, Yuhan Wang, Yi Tai, Jing Han, Yanjin Zheng, Can Wang, Hong Xiang Zuo, Ming Yue Li, Yue Xing, Xuejun Jin, Juan Ma
{"title":"葫芦素B通过靶向ZNF70抑制NLRP3/STAT3信号轴减轻dss诱导的实验性结肠炎。","authors":"Shen Cao, Yuhan Wang, Yi Tai, Jing Han, Yanjin Zheng, Can Wang, Hong Xiang Zuo, Ming Yue Li, Yue Xing, Xuejun Jin, Juan Ma","doi":"10.1007/s10787-025-01898-5","DOIUrl":null,"url":null,"abstract":"<p><p>Ulcerative colitis (UC) is an inflammatory disease characterized by lifelong involvement and a complex pathogenesis. Due to the limitations of current treatment modalities, there remains a pressing need to discover new medications for the management of UC. Cucurbitacin B (CuB) is a tetracyclic triterpenoid derived from Lagenaria siceraria (Molina) Standl., exhibiting pharmacological activities including hepatoprotective, anti-inflammatory, and anti-tumor properties. In this study, we conducted a comprehensive evaluation of the anti-inflammatory activity of CuB in both DSS-induced experimental colitis in vivo and macrophage models in vitro. Our results indicate that CuB exerts an anti-inflammatory effect by regulating the assembly of the NLRP3 inflammasome and the activation of p-STAT3 via ZNF70, thereby reducing the release of pro-inflammatory cytokines, including IL-1β, IL-6, and TNF-α. Such results indicate that CuB can effectively prevent the development of UC and offer new insights for its management.</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":"5451-5469"},"PeriodicalIF":5.3000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cucurbitacin B alleviates DSS-induced experimental colitis by targeting ZNF70 to suppress the NLRP3/STAT3 signaling axis.\",\"authors\":\"Shen Cao, Yuhan Wang, Yi Tai, Jing Han, Yanjin Zheng, Can Wang, Hong Xiang Zuo, Ming Yue Li, Yue Xing, Xuejun Jin, Juan Ma\",\"doi\":\"10.1007/s10787-025-01898-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Ulcerative colitis (UC) is an inflammatory disease characterized by lifelong involvement and a complex pathogenesis. Due to the limitations of current treatment modalities, there remains a pressing need to discover new medications for the management of UC. Cucurbitacin B (CuB) is a tetracyclic triterpenoid derived from Lagenaria siceraria (Molina) Standl., exhibiting pharmacological activities including hepatoprotective, anti-inflammatory, and anti-tumor properties. In this study, we conducted a comprehensive evaluation of the anti-inflammatory activity of CuB in both DSS-induced experimental colitis in vivo and macrophage models in vitro. Our results indicate that CuB exerts an anti-inflammatory effect by regulating the assembly of the NLRP3 inflammasome and the activation of p-STAT3 via ZNF70, thereby reducing the release of pro-inflammatory cytokines, including IL-1β, IL-6, and TNF-α. Such results indicate that CuB can effectively prevent the development of UC and offer new insights for its management.</p>\",\"PeriodicalId\":13551,\"journal\":{\"name\":\"Inflammopharmacology\",\"volume\":\" \",\"pages\":\"5451-5469\"},\"PeriodicalIF\":5.3000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Inflammopharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s10787-025-01898-5\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/12 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Inflammopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10787-025-01898-5","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/12 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

溃疡性结肠炎(UC)是一种终身性炎症性疾病,发病机制复杂。由于目前治疗方式的局限性,迫切需要发现治疗UC的新药物。葫芦素B (Cucurbitacin B, CuB)是一种从Lagenaria siceraria (Molina) Standl中提取的四环三萜化合物。,具有保护肝脏、抗炎和抗肿瘤的药理活性。在本研究中,我们对CuB在dss诱导的实验性结肠炎的体内和体外巨噬细胞模型中的抗炎活性进行了综合评价。我们的研究结果表明,CuB通过ZNF70调节NLRP3炎症小体的组装和p-STAT3的激活,从而减少促炎细胞因子的释放,包括IL-1β、IL-6和TNF-α,从而发挥抗炎作用。这些结果表明,CuB可以有效地预防UC的发展,并为UC的管理提供新的见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Cucurbitacin B alleviates DSS-induced experimental colitis by targeting ZNF70 to suppress the NLRP3/STAT3 signaling axis.

Ulcerative colitis (UC) is an inflammatory disease characterized by lifelong involvement and a complex pathogenesis. Due to the limitations of current treatment modalities, there remains a pressing need to discover new medications for the management of UC. Cucurbitacin B (CuB) is a tetracyclic triterpenoid derived from Lagenaria siceraria (Molina) Standl., exhibiting pharmacological activities including hepatoprotective, anti-inflammatory, and anti-tumor properties. In this study, we conducted a comprehensive evaluation of the anti-inflammatory activity of CuB in both DSS-induced experimental colitis in vivo and macrophage models in vitro. Our results indicate that CuB exerts an anti-inflammatory effect by regulating the assembly of the NLRP3 inflammasome and the activation of p-STAT3 via ZNF70, thereby reducing the release of pro-inflammatory cytokines, including IL-1β, IL-6, and TNF-α. Such results indicate that CuB can effectively prevent the development of UC and offer new insights for its management.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Inflammopharmacology
Inflammopharmacology IMMUNOLOGYTOXICOLOGY-TOXICOLOGY
CiteScore
8.00
自引率
3.40%
发文量
200
期刊介绍: Inflammopharmacology is the official publication of the Gastrointestinal Section of the International Union of Basic and Clinical Pharmacology (IUPHAR) and the Hungarian Experimental and Clinical Pharmacology Society (HECPS). Inflammopharmacology publishes papers on all aspects of inflammation and its pharmacological control emphasizing comparisons of (a) different inflammatory states, and (b) the actions, therapeutic efficacy and safety of drugs employed in the treatment of inflammatory conditions. The comparative aspects of the types of inflammatory conditions include gastrointestinal disease (e.g. ulcerative colitis, Crohn''s disease), parasitic diseases, toxicological manifestations of the effects of drugs and environmental agents, arthritic conditions, and inflammatory effects of injury or aging on skeletal muscle. The journal has seven main interest areas: -Drug-Disease Interactions - Conditional Pharmacology - i.e. where the condition (disease or stress state) influences the therapeutic response and side (adverse) effects from anti-inflammatory drugs. Mechanisms of drug-disease and drug disease interactions and the role of different stress states -Rheumatology - particular emphasis on methods of measurement of clinical response effects of new agents, adverse effects from anti-rheumatic drugs -Gastroenterology - with particular emphasis on animal and human models, mechanisms of mucosal inflammation and ulceration and effects of novel and established anti-ulcer, anti-inflammatory agents, or antiparasitic agents -Neuro-Inflammation and Pain - model systems, pharmacology of new analgesic agents and mechanisms of neuro-inflammation and pain -Novel drugs, natural products and nutraceuticals - and their effects on inflammatory processes, especially where there are indications of novel modes action compared with conventional drugs e.g. NSAIDs -Muscle-immune interactions during inflammation [...]
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信